STUDY GOALS AND OBJECTIVES
The aim of this report is to provide a range of information—from detailed analysis through industry trends—to quantify and qualify the rapidly growing market for therapeutic monoclonal antibody (mAb) drugs. Forecasts and trends are gleaned from industry sources, analyst reports, and company forecasts, as well as from assessment of available and emerging technologies.
The report develops forecasts for sales of the mAb market by individual antibody, by therapeutic antibody target (epidermal growth factor receptor [EGFR], cluster of differentiation [CD] 20, tumor necrosis factor [TNF] alpha, etc.), and by major disease applications from 2011 through 2016. Additionally, we examine strategies employed by biopharmaceutical firms to develop and market products in this explosive market sector.
Our main objective is to present a comprehensive analysis of the current market for therapeutic mAb disease-modifying products and to forecast this market’s future direction through 2016.
REASONS FOR DOING THE STUDY
Therapeutic mAbs represent the largest and one of the fastest-growing classes of biopharmaceutical products by sales in the U.S. and throughout the world. Of the top 20 drugs by sales throughout the world today, five are mAbs.
During our forecast period from 2011 through 2016, eight new mAbs are forecast to enter the market, and sales of therapeutic mAbs are estimated to grow from approximately $43 billion in 2010 to nearly $58 billion in 2016. Sales of humanized and fully human antibodies for autoimmune/inflammatory diseases such as rheumatoid arthritis, ulcerative colitis, and multiple sclerosis are forecast to experience the fastest sales growth.
This period of dynamic growth for humanized and fully human antibodies plus the continued rollout of antibody-drug conjugates (ADCs), also called immunoconjugates, is expected to result in stagnating sales of chimeric antibodies from 2011 through 2016.
This study will be of interest to those working in the biotechnology and pharmaceutical industries and related life science, drug discovery, and diagnostic test manufacturing companies, as well as all those interested or actively working in drug research.
Both individuals looking for a comprehensive listing of mAbs in human clinical-stage development and individuals looking at how the mAb drug marketplace is expected to change (in terms of sales and technology) in the coming years will find this report extremely useful.
SCOPE OF REPORT
This report analyzes and assesses therapeutic applications of mAbs in human medicine. Covered in this report are mAbs exclusively, including the combination of mAbs when they are attached to a cytotoxic agent such as with ADCs.
Excluded from this report are diagnostic uses of mAbs (such as for imaging purposes) and therapeutic antibodies for veterinary use. Also excluded are research applications of mAbs.
The scope of the study is global. The “Overview” section provides a discussion of the importance and advantages of antibody-based products, valuation of antibody product sales, patent issues and differences in applicability of mAbs products versus polyclonal antibodies (pAbs), and other competing agents such as small molecule therapeutics.
The “Technology and Technical Issues” section discusses new directions in antibody research, the types of antibodies used as therapeutics, the challenges in antibody production, and other approaches—in particular transgenic sources—of antibody production.
The “Products” section provides a synopsis of more than 60 mAb drugs, including those currently marketed and those in late-stage development. Comparative product and sales analyses are provided for individual products. Tables include current and forecasted sales by individual product, sales by target and technology (for mAb-based drugs), as well as global market size and growth estimates for therapeutic mAbs.
The “Applications” section provides an overview of the leading indications for available and emerging antibody-based therapeutics. These include selected indications for autoimmune diseases (specifically rheumatoid arthritis, psoriasis, and Crohn’s disease), cancer indications (specifically the most common solid tumor types, leukemias, and lymphomas) cardiovascular diseases, infectious diseases, ophthalmic indications, and respiratory diseases.
The “Industry Structure” section provides an overview of the antibody industry as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
The “Company Profiles” section emphasizes companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.
More Antibody Technologies reports by BCC Research
Antibody Drug Conjugates: Technologies and Global Markets by BCC Research
Antibody Drug Conjugates: Technologies and Global Markets
The global market for ADC drugs reached $179 million in 2012 and $396 million in 2013. The market ...
Global Markets and Manufacturing Technologies for Protein Drugs - Focus on Cytokines and Monoclonal Antibodies by BCC Research
Global Markets and Manufacturing Technologies for Protein Drugs - Focus on Cytokines and Monoclonal Antibodies
This report will provide:
An overview of the markets for ...
Single-Use Technologies for Biopharmaceuticals: Global Markets by BCC Research
This report provides:
An overview of biopharmaceutical single-use technologies, which aids the manufacturing process in overcoming such complex issues as sterilization and critical manufacturing parameters
See all reports like this >>
Kinase Inhibitors: Global Markets by BCC Research
The global kinase inhibitors market reached $28.1 billion in 2010 and nearly $29.1 billion in 2011. The market is expected to reach $40.2 billion by ...
More Global Antibody Technologies reports
Single Use Bioreactor Market by Product Type (Recombinant Proteins, Monoclonal Antibodies), Cell Type (Bacteria, Yeast), Technology (Stirred SUB, Single Use Bubble Column Bioreactor), End User(Bio pharmaceutical Manufacturers) - Global Forecast to 2019 by MarketsandMarkets
Single Use Bioreactor Market by Product Type (Recombinant Proteins, Monoclonal Antibodies), Cell Type (Bacteria, Yeast), Technology (Stirred SUB, Single Use Bubble Column Bioreactor), End User(Bio ...
Global Biologic Therapeutics Market 2014-2018 by TechNavio - Infiniti Research Ltd.
Global Biologic Therapeutics Market 2014-2018About Biologic TherapeuticsBiologic therapeutics include virus, therapeutic serum, toxin, allergenic product, antitoxin, blood component or derivative, vaccine, blood, protein (except any ...
Global and China Monoclonal Antibody Industry Report, 2014-2019 by Research in China
Global and China Monoclonal Antibody Industry Report, 2014-2019Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody ...
See all reports like this >>
Lyophilization Market by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, & Others), Technology (Tray-style, Manifold, & Rotary) & Geography - Global Trends & Forecast to 2019 by MarketsandMarkets
Lyophilization Market by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, & Others), Technology (Tray-style, Manifold, & Rotary) & Geography ...